Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Clinical Trial ● Currently Recruiting NCT07354971

IMMUNO-FIT Observational Study

IMMUNO-FIT Observational Study — Recruiting • Oncology • NCT07354971.

📅 28 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
NCT ID
NCT07354971
Sponsor
University Hospital Southampton NHS Foundation Trust
Start
2026-03-26
ClinicaliQ Trial Snapshot
  • IMMUNO-FIT Observational Study — Recruiting • Oncology • NCT07354971.
  • Sponsor: University Hospital Southampton NHS Foundation Trust.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

This observational study will investigate how immunotherapy affects physical fitness, quality of life, and treatment tolerance in adults with solid cancers. Immunotherapy can cause a range of side effects that impact daily functioning and may lead to treatment delays or early discontinuation. Physical fitness may influence how well patients cope with treatment, yet little is known about how fitness changes during immunotherapy or whether baseline fitness is linked to outcomes. Participants will complete fitness testing using cardiopulmonary exercise testing (CPET) and quality-of-life questionnaires before starting immunotherapy and again 12 weeks…

Eligibility Snapshot
  • : * Age ≥18 years * Histologically confirmed solid malignancy * Receiving immune checkpoint inhibitors in one of the following settings: * Adjuvant: Single-agent anti-PD-1, anti-PD-L1, or anti-CTLA-4 * Metastatic/Palliative: Single-agent or dual-agent anti-PD-1, anti-PD-L1, or anti-CTLA-4 * ECOG Performance Status 0-2 * Able to perform cardiopulmonary exercise testing * Able to provide written informed consent * Willing and able to comply with study procedures and follow-up schedule

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
Oesophago-Gastric Cancer: Assessment and Management (NICE NG83)
Oncology · 27 Mar 2026
Multimodal treatment with neoadjuvant chemotherapy followed by surgical resection improves survival for locally advanced oesophago-gastric junction and gastric adenocarcinomas. HER2 testing is…
View guideline →
Guideline
Colorectal Cancer: Diagnosis and Management (NICE NG151)
Oncology · 27 Mar 2026
Refer adults with rectal bleeding plus abdominal pain, change in bowel habit, weight loss, iron-deficiency anaemia, or age >60 with unexplained symptoms…
View guideline →
Guideline
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer
Oncology · 06 May 2026
Test for BRAF V600E mutation in patients with advanced NSCLC before considering encorafenib plus binimetinib, as this combination is only recommended for…
View guideline →
Clinical Brief
NHS cancer jab could mean patients spend hours less in hospital
Oncology · BBC Health · 03 May 2026
Injectable immunotherapy formulation reduces administration time from hours to minutes, potentially decreasing hospital visits and improving patient experience Thousands of NHS cancer…
View brief →
Guideline
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors
Oncology · 28 Apr 2026
Ripretinib is recommended as an option for adults with advanced gastrointestinal stromal tumours who have received 3 or more prior kinase inhibitors…
View guideline →
Guideline
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable locally advanced head and neck squamous cell carcinoma
Oncology · 21 Apr 2026
Pembrolizumab is recommended as neoadjuvant treatment prior to surgery for resectable locally advanced head and neck squamous cell carcinoma, followed by adjuvant…
View guideline →